S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
Log in
(Ad)
And Reuters magazine calls this type of trading "the new baby boomer hobby." An anonymous trader -- living at the base of the Smoky Mountains -- just released a free report revealing a step-by-step system to generating an extra $5,000 per month in income thanks to this trading strategy. The report is free until Sunday.

NASDAQ:SGEN - Seattle Genetics Stock Price, Forecast & News

$115.35
+3.65 (+3.27 %)
(As of 01/23/2020 04:00 PM ET)
Add
Compare
Today's Range
$111.00
Now: $115.35▼
$115.75
50-Day Range
$105.47
MA: $112.91▼
$117.50
52-Week Range
$62.90
Now: $115.35▼
$122.36
Volume1.19 million shs
Average Volume968,920 shs
Market Capitalization$19.77 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. Read More…

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGEN
Previous Symbol
CUSIP81257810
CIK1060736
Webhttp://www.seattlegenetics.com/
Phone425-527-4000

Debt

Debt-to-Equity RatioN/A
Current Ratio4.86
Quick Ratio4.49

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$654.70 million
Price / Sales30.20
Cash FlowN/A
Price / Cash FlowN/A
Book Value$7.95 per share
Price / Book14.51

Profitability

EPS (Most Recent Fiscal Year)($1.65)
Net Income$-222,690,000.00
Net Margins-37.97%
Return on Equity-19.17%
Return on Assets-15.99%

Miscellaneous

Employees1,302
Outstanding Shares171,386,000
Market Cap$19.77 billion
Next Earnings Date2/6/2020 (Confirmed)
OptionableOptionable

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

NASDAQ:SGEN Rates by TradingView

(Ad)

CNN calls 5G "the lifeblood of the new economy."

If you don't invest now, you'll regret it later.

Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) released its quarterly earnings results on Tuesday, October, 29th. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.19. The biotechnology company had revenue of $213.26 million for the quarter, compared to analyst estimates of $211.85 million. Seattle Genetics had a negative return on equity of 19.17% and a negative net margin of 37.97%. The firm's quarterly revenue was up 25.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.42) EPS. View Seattle Genetics' Earnings History.

When is Seattle Genetics' next earnings date?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Seattle Genetics.

How can I listen to Seattle Genetics' earnings call?

Seattle Genetics will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for SGEN?

19 brokers have issued 1 year price targets for Seattle Genetics' stock. Their forecasts range from $95.00 to $140.00. On average, they anticipate Seattle Genetics' stock price to reach $114.73 in the next year. This suggests that the stock has a possible downside of 0.5%. View Analyst Price Targets for Seattle Genetics.

What is the consensus analysts' recommendation for Seattle Genetics?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seattle Genetics.

What are Wall Street analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:
  • 1. According to Zacks Investment Research, "Seattle Genetics reported narrower-than-expected loss in Q1 while revenues beat estimates.Its sole marketed drug, Adcetris, is performing well since its launch. Adcetris’ recent label expansion in frontline stage III/IV Hodgkin lymphoma and in frontline CD30-expressing peripheral T-cell lymphomas (PTCL) bodes well for the company. The company’s collaboration with Takeda for the global development and commercialization of Adcetris also holds promise. However, its heavy dependence solely on Adcetris for growth is a concern. The recent label expansion of Merck’s Keytruda and Bristol-Myers’ Opdivo in the lymphoma indication will increase competition. Though the company has multiple candidates in its pipeline, maximum is in early developmental stages. Any regulatory setback for Adcetris could hurt its sales potential significantly." (5/29/2019)
  • 2. JPMorgan Chase & Co. analysts commented, "Quarter as We maintain our Neutral rating on ZBH shares following 1Q19 results that came in-line with Street expectations (but missed our more bullish forecast) on the top-line with slightly higher expenses than we forecasted. While Hips (+1.7% xFx) and Dental (-0.2% xFx) were bright spots relative to expectations, Knees (+0.7% xFx) continues to remain challenged relative to market growth particularly within the Americas (-0.9% xFx). Importantly volume gains overall were +220bps Y/Y and only negative 30bps Q/Q from a seasonally strong 4Q18. While pricing pressures have not abated, we think the volume gains are notable for ZBH considering the overall pricing environment seen across all large cap orthopedics thus far this season." (4/28/2019)
  • 3. HC Wainwright analysts commented, "We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($63.1 HL + $3.6 relapsed sALCL+ $11.2 frontline PTCL + $17.6 platform + $2.6 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing. Seattle Genetics Inc. April 26, 2019 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2Seattle Genetics, Inc." (4/26/2019)

Has Seattle Genetics been receiving favorable news coverage?

News headlines about SGEN stock have trended somewhat positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Seattle Genetics earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Seattle Genetics.

Who are some of Seattle Genetics' key competitors?

What other stocks do shareholders of Seattle Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seattle Genetics investors own include Immunomedics (IMMU), Gilead Sciences (GILD), Celgene (CELG), AbbVie (ABBV), Netflix (NFLX), Incyte (INCY), NVIDIA (NVDA), Alibaba Group (BABA), Alexion Pharmaceuticals (ALXN) and Micron Technology (MU).

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the folowing people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 58)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 58)
  • Dr. Vaughn B. Himes, Chief Technology Officer (Age 58)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 62)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 51)

Who are Seattle Genetics' major shareholders?

Seattle Genetics' stock is owned by many different of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.28%), Candriam Luxembourg S.C.A. (0.22%), Rhenman & Partners Asset Management AB (0.07%), Gateway Investment Advisers LLC (0.02%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Tributary Capital Management LLC (0.01%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, David W Gryska, Jean I Liu, Jonathan G Drachman, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

Which institutional investors are selling Seattle Genetics stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Rhenman & Partners Asset Management AB, Gateway Investment Advisers LLC, Tocqueville Asset Management L.P., Zurcher Kantonalbank Zurich Cantonalbank , Tributary Capital Management LLC and IFM Investors Pty Ltd. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

Which institutional investors are buying Seattle Genetics stock?

SGEN stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Alpine Global Management LLC, Leavell Investment Management Inc., Clarus Wealth Advisors, DNB Asset Management AS, Carroll Financial Associates Inc., Janney Montgomery Scott LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Seattle Genetics.

How do I buy shares of Seattle Genetics?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of SGEN stock can currently be purchased for approximately $115.35.

How big of a company is Seattle Genetics?

Seattle Genetics has a market capitalization of $19.77 billion and generates $654.70 million in revenue each year. The biotechnology company earns $-222,690,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. Seattle Genetics employs 1,302 workers across the globe.View Additional Information About Seattle Genetics.

What is Seattle Genetics' official website?

The official website for Seattle Genetics is http://www.seattlegenetics.com/.

How can I contact Seattle Genetics?

Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]


MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  624 (Vote Outperform)
Underperform Votes:  628 (Vote Underperform)
Total Votes:  1,252
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: What is a Call Option?
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel